fda warning letter glp-1 october 2025 News Archives – Partnership for Safe Medicines Trends In FDA FY2022 Inspection-based

The effects of switching from dipeptidyl peptidase-4 inhibitors to glucagon-like peptide-1 receptor agonists on bone mineral density in diabetic patients

Mitochondria dysfunction in CD8+ T cells as an important contributing factor for cancer development and a potential target for cancer treatment: a review

Engineered Clostridium butyricum -pMTL007-GLP-1 Delays Neurodegeneration in Prnp-SNCA*A53T Transgenic Mice Model by Suppressing Astrocyte Senescence

The direct defective of insulin signaling As has been mentioned, the proper modulators acting on different steps of the signaling pathway ensure appropriate biological responses to insulin in different tissues

Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis

In another clinical trial, AD patients were treated with steroids and climatotherapy in the Dead Sea in 2 groups